[Monoclonal gammopathies--from MGUS to myeloma].
Monoclonal gammopathies are characterized by the overproduction of a monoclonal immunoglobulin (M-Protein), which may be detected in serum or urine by protein electrophoresis and immunofixation. The presence of an M-Protein results from the proliferation of a single abnormal clone of differentiated B lymphocytes or plasma cells, and is associated with a variety of clinical conditions, ranging from asymptomatic to malignant disease. Recent years have witnessed considerable advances in the treatment of plasma cell myeloma, the most common malignant disorder of the monoclonal gammopathies. As compared with conventional-dose treatments, high-dose chemotherapy with autologous stem-cell transplantation increases response rates and overall survival of patients with myeloma who are younger than 65 years of age. Progress in supportive therapies and the development of promising new drugs such as proteasome inhibitors and thalidomide analogues may provide further benefits for myeloma patients in the future.
Hess
U
U
Fachbereich Onkologie/Hämatologie, Kantonsspital St. Gallen. urs.hess@kssg.ch
Heijnen
I A F M
IA
D003937:Diagnosis, Differential; D006403:Hematologic Tests; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy; D009194:Myeloma Proteins / Q000652:urine; D010265:Paraproteinemias / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate
D009194:Myeloma Proteins; C085016:multiple myeloma M-proteins